Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42
Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ: HELP ) with a Buy and lowers the price target from $45 to $42.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.